nach oben

Erschienen in:

01.02.2016 | Review Article

Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review

verfasst von: Ronald Chow, Leonard Chiu, Rudolph Navari, Steven Passik, Nicholas Chiu, Marko Popovic, Henry Lam, Mark Pasetka, Edward Chow, Carlo DeAngelis

Erschienen in: Supportive Care in Cancer | Ausgabe 2/2016

Einloggen, um Zugang zu erhalten

Abstract

Introduction

Olanzapine is an atypical antipsychotic drug that inhibits serotonergic, dopaminergic, alpha-1 adrenergic, histaminic, and muscarinic receptors. Several phase I and II trials have been published documenting the use of olanzapine in controlling chemotherapy-induced nausea and vomiting (CINV). This review aims to summarize all phase I and II trials that reported on olanzapine for the prophylaxis of CINV.

Methods

A literature search was conducted in Ovid MEDLINE from 1946 to July week 1 2015, Embase Classic and Embase from 1947 to 2015 week 28, and the Cochrane Central Register of Controlled Trials up until June 2015. Phase I and II trials reporting on olanzapine for the prophylaxis for CINV were included if they reported on at least one of four primary endpoints: complete response (CR), complete control (CC), no nausea, and no emesis. Other endpoints of interest included the safety of olanzapine as measured by the M.D. Anderson Symptom Inventory.

Results

Across the seven included studies, there were a total of 201 patients. The CR across four studies was 97.2, 83.1, and 82.8 % for the acute, delayed, and overall phases, respectively. The CC for acute, delayed, and overall phases was 92.5, 87.5, and 82.5 %, respectively. The overall no nausea rate was 92.7, 71.8, and 70.6 % for the acute, delayed, and overall phases, respectively. The overall no emesis rates for the acute, delayed, and overall phases were 100, 94.5, and 90.4 %, respectively. Fatigue, drowsiness, and disturbed sleep were common side effects.

Conclusion

Olanzapine is efficacious and safe when used as a prophylaxis for CINV.

Osoba D, Zee B, Warr D, Latreille J, Kaizer L, Pater J (1997) Effect of postchemotherapy nausea and vomiting on health-related quality of life. Support Care Cancer 5(4):307–313PubMedCrossRef

Bymaster FP, Calligaro D, Falcone J, Marsh R, Moore N, Tye N et al (1996) Radio-receptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96PubMedCrossRef

Srivastava M, Brito-Dellan N, Davis MP, Leach M, Lagman R (2003) Olanzapine as an antiemetic in refractory nausea and vomiting in advanced cancer. J Pain Symptom Manage 25(6):578–582PubMedCrossRef

Pirl WF, Roth AJ (2000) Remission of chemotherapy-induced emesis with concurrent olanzapine treatment: a case report. Psychooncology 9:84–87PubMedCrossRef

Abe M, Hirashima Y, Kasamatsu Y, Kado N, Komeda S, Kuji S et al. (2015) Efficacy and safety of olanzapine combined with aprepitant, palonosetron and dexamethasone for preventing nausea and vomiting by cisplatin-based chemotherapy in gynecological cancer: KCOG-G1303 phase II trial. Supp Care Canc. doi:10.1007/s00520-015-2829-z

Park S, Choi C, Kwon M, Tae J, Kim H (2015) A phase II trial of palonosetron and olanzapine without dexamethasone for the prevention of chemotherapy-induced nausea and vomiting. Supp Care Canc 23(Suppl 1):S147

Navari R, Einhorn L, Passik S, Loehrer P, Johnson C, Mayer M et al (2005) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a hoosier oncology group study. Support Care Cancer 13:529–534PubMedCrossRef

Navari R, Einhorn L, Loehrer P, Passik S, Vinson J, McClean J et al (2007) A phase II trial of olanzapine for the prevention of chemotherapy-induced nausea and vomiting: a hoosier oncology group study. Support Care Cancer 15:1285–1291PubMedCrossRef

Passik S, Kirsh K, Theobald D, Dickerson P, Trowbridge R, Gray D et al (2003) A retrospective chart review of the use of olanzapine for the prevention of delayed emesis in cancer patients. J Pain Symptom Manage 25(5):485–489PubMedCrossRef

10.

Passik S, Navari R, Jong S, Nagy C, Vinson J, Kirsh K et al (2004) A phase I trial of olanzapine (zyprexa) for the prevention of delayed emesis in cancer patients: a hoosier oncology group study. Cancer Invest 22(3):383–388PubMedCrossRef

11.

Passik S, Lundberg J, Kirsh K, Theobald D, Donaghy K, Holtsclaw E et al (2002) A pilot exploration of the antiemetic activity of olanzapine for the relief of nausea in patients with advanced cancer and pain. J Pain Symptom Manage 23(6):526–532PubMedCrossRef

12.

Wang X, Feng Y, Chen Y, Gao B, Han B (2014) A meta-analysis of olanzapine for the prevention of chemotherapy-induced nausea and vomiting. Sci Rep 4:4813PubMed

13.

Mayberg H, Silva J, Brannan S, Tekell J, Mahurin R, McGinnis S et al (2002) The functional neuroanatomy of the placebo effect. Am J Psychiatr 159(5):728–737PubMedCrossRef

Titel: Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review
verfasst von: Ronald Chow
Leonard Chiu
Rudolph Navari
Steven Passik
Nicholas Chiu
Marko Popovic
Henry Lam
Mark Pasetka
Edward Chow
Carlo DeAngelis
Publikationsdatum: 01.02.2016
Verlag: Springer Berlin Heidelberg
Erschienen in: Supportive Care in Cancer / Ausgabe 2/2016
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI: https://doi.org/10.1007/s00520-015-3000-6

Neu im Fachgebiet Onkologie

Umsetzung der POMGAT-Leitlinie läuft

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Springer Medizin

Efficacy and safety of olanzapine for the prophylaxis of chemotherapy-induced nausea and vomiting (CINV) as reported in phase I and II studies: a systematic review